StuartLeighGoldbergMD

Oncology • North Bergen, NJ

John Theurer Cancer Center at Hackensack University Medical Center

Join to view full profile

Dr. Goldberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldberg's full profile

Already have an account?

Office
7650 River Rd
North Bergen, NJ 07047
Phone+1 201-464-0008

Fax+1 201-662-1267

Summary

Stuart Goldberg MD currently serves as the Chief, Division of Outcomes and Value Research at the John Theurer Cancer Center, and previously was a Chief Division of Leukemia and Member of the Center's Bone Marrow Transplant Program. He is involved in the clinical care of patients with Acute and Chronic Leukemia, MDS and other bone marrow failure diseases. The program is an MDS Foundation Center of Excellence (and serves on the MDS Foundations Development Board), and Dr Goldberg is a medical advisor to the NJ Leukemia Society. He is the principal investigator of over 30 active trials and currently an international co-chair on the SIMPLICTY CML trial. Dr Goldberg lectures extensively on various topics and has discussed the role of chelation therapy in MDS on 5 different continents. Dr Goldberg also served as the Chief Medical Officer of COTA Inc, a medical data and analytics company founded at the John Theurer Cancer Center. COTA seeks to find value in healthcare.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1991 - 1992
George Washington UniversityFellowship, Hematology and Medical Oncology, 1989 - 1991
George Washington UniversityResidency, Internal Medicine, 1986 - 1989
Pennsylvania State University College of MedicineClass of 1986

Certifications & Licensure

NJ State Medical License 1998 - 2025
DC State Medical License 2019 - 2020
PA State Medical License 1989 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

David King Clinical Scientist Award Association of Community Cancer Centers, 2016
Inside Jersey Top Doctors for Cancer Castle Connolly, 2012-2015
Inside Jersey Magazine Top Doctors Castle Connolly, 2012-2015
Top Doctors: New York Metro Area Castle Connolly, 2011-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Join now to see all

Clinical Trials

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer Start of enrollment: 2015 Apr 01
Terminated
Join now to see all

Publications & Presentations

PubMed

263 citations
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Andreas Hochhaus, Michele Baccarani, Michael W. Deininger, Jane F. Apperley, Jeffrey H. Lipton
Leukemia. 2008-01-01
434 citations
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus, Hagop M. Kantarjian, Michele Baccarani, Jeffrey H. Lipton, Jane F. Apperley
Blood. 2007-03-15
143 citations
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
Stefan Faderl, Meir Wetzler, David A. Rizzieri, Gary J. Schiller, Madan Jagasia
Journal of Clinical Oncology. 2012-05-14

Journal Articles

Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML
Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood

Abstracts/Posters

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chr...
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multipl...
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Phil...
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma
Stuart L. Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloi...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

New Model Can Help Clinicians to Predict 40-Day Mortality Risk in Hospitalized COVID-19 PatientsAugust 2nd, 2021
On the Front Lines During the First Wave of COVID-19 Pandemic: Hackensack Meridian Health PublishingJune 5th, 2020
Hope Dims for Hydroxychloroquine Even as Medical Study Detailing the Drug’s Failure Is RetractedJune 5th, 2020
Join now to see all